Tag Archives: technology

Hot Investor Mandate: VC Firm Backed By Major Financial Services Group Seeks Co-Investment Opportunities in Early-Stage Therapeutics and Medtech Sectors

15 Jul

A venture capital firm backed by a major global financial services group actively invests across multiple sectors, including life sciences. The firm typically invests USD 1–2 million per round, though it is capable of larger allocations depending on the opportunity. While globally active, the firm focuses on opportunities with strong relevance to specific market needs in Asia. 

In the life sciences space, the firm is currently targeting therapeutic and medtech products that address major unmet medical needs in its home market. It favors companies with a clear strategy to collaborate with regional pharmaceutical partners, whether through licensing, co-development, or strategic equity participation. The firm considers a range of therapeutic modalities including small molecules, biologics, biosimilars, and reformulated drugs. It primarily seeks products in Phase I clinical trials but may also invest in assets within one year of entering the clinic. Indications of strong interest include oncology and orphan diseases. 

The firm only co-invests in opportunities outside of its home country and strongly prefers that a reputable institutional lead or established syndicate be in place before participating. As such, it tends to evaluate international deals with a co-investment mindset alongside other institutional investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: Global Investment Firm Seeks Early-Stage Healthcare Companies Including Devices and Digital Health Targeting Diabetes and Related Conditions

8 Jul

A Europe-based venture capital firm manages a dedicated fund focused on diabetes and related conditions. Its investment sweet spot ranges from Seed to Series A, with typical check sizes between $1–3 million. The firm invests globally and is open to both leading and co-investing. Its team brings strong scientific and industry expertise in the diabetes space and actively supports portfolio companies, including through board and observer roles. 

The firm focuses on diabetes and related indications such as comorbidities or conditions where diabetes is a key driver (e.g., kidney disease, wound care, and vision loss). It primarily invests in medical devices and digital health solutions, avoiding traditional biotech therapeutics. For hardware, the firm seeks technologies beyond the prototype stage with early data (lab, clinical, or first-in-human). For software, it prioritizes products showing commercial traction or scalable business models. For B2B products, validation through partnerships with medtech firms or healthcare systems is a strong advantage. 

There are no specific requirements regarding a company’s founding team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: US-Based VC Firm Invests in Seed to Series A Medical Device Companies Backed By Female and Minority Founding Teams

8 Jul

A US-based venture capital firm with a hands-on investment approach and a strong commitment to supporting underrepresented founders  invests at the Seed and Series A stages, typically leading rounds with initial check sizes of up to $2 million in equity. The firm makes approximately 1-3 new investments per year and focuses on companies based in the United States. 

Within life sciences, the firm invests in disruptive technologies in the medical device sector and is open to all classes of medical devices. 

The firm is dedicated to backing diverse founding teams. Its current portfolio includes a significant proportion of companies led by women and minorities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: VC Firm Invests Up to €20M in US and Europe-Based Device, Diagnostics, and Digital Health Companies

8 Jul

A venture capital firm based in Western Europe invests in healthcare companies with typical check sizes ranging from €1–20 million, usually entering at the second or third round of financing and participating through Series B. The firm focuses on companies based in the U.S. and Europe. 

The firm invests in diagnostics, digital health, and medical devices, but does not invest in drugs, biotech, or therapeutics. The firm targets companies in the in-development or clinical stages and is indication-agnostic. 

The firm does not have specific requirements for management teams and typically takes a board or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: US-Based VC Firm Seeks New Therapeutics and Medical Device Investment Opportunities, Investing Up to $20M

8 Jul

A venture capital firm with offices in the US typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $20 million throughout a portfolio company’s path to liquidity. 
 
The firm is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has invested in biopharmaceutical companies focused on developing drugs to treat enteral feeding intolerance and disorders that are driven by CD47-mediated signaling pathways, including leukemia, lymphoma, solid tumors, and pulmonary hypertension. In addition, the firm has invested in a medical device developing a minimally-invasive, catheter-based device to re-create valves in deep leg veins. The firm does not look at diagnostics, though may be interested in technology with real-time feedback for procedures. 
 
The firm focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the firm is able to help entrepreneurs achieve near-term objectives that position their companies for exit. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Introducing BioVenture Voices: A New Segment in Next Phase 

8 Jul

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022Life Science Nation (LSN) is excited to introduce a new segment to our weekly Next Phase newsletter: BioVenture Voices, a collaborative feature powered by BioTechTV. This series highlights the personal stories, lessons, and perspectives of founders, investors, and industry leaders driving early-stage innovation across biotech, medtech, diagnostics, and digital health.

BioVenture Voices captures candid interviews with people navigating the complex path from scientific breakthroughs to market-ready products. Whether you’re an entrepreneur seeking capital, an investor tracking emerging trends, or a strategic partner scouting for innovation, these conversations offer unfiltered viewpoints and practical takeaways straight from those in the trenches.

In alignment with LSN’s mission to connect innovative startups with early-stage investors and partners, BioVenture Voices adds a human dimension to the investment landscape—featuring voices you might meet on the RESI partnering platform, in the Exhibition Hall, or on stage during an Innovator’s Pitch Challenge session.

Starting this week, readers can look forward to regular installments of BioVenture Voices in Next Phase, offering an up-close look at the minds behind science. Watch, listen, and learn from the stories shaping the future of healthcare innovation.

To launch the series, we’re pleased to share an interview with Bryan Roberts, Partner at Venrock, who reflects on the evolution of venture investing in biotech, what he looks for in early-stage opportunities, and how the relationship between founders and investors has changed over time.

RESI Boston Webinar Series: Your Roadmap to a Stronger Pitch, Smarter Partnering, and Greater Investor Engagement 

8 Jul

By Max Braht, Director of Business Development, LSN

Max-Braht-HeadshotRESI Boston returns September 17 to 19, 2025, and in the lead-up to the event, Life Science Nation is offering a series of free educational webinars designed to help life science startups strengthen their pitch, navigate partnering, and engage more effectively with investors. Whether you are pitching at the Innovator’s Pitch Challenge, booking one-on-one meetings, or attending RESI for the first time, these sessions offer valuable tools to get the most out of your conference experience.

July 10, 2025 at 12:00 PM
Standing Out to Investors: How to Tell Your Startup Story for Maximum Impact – Sign Up
The most successful entrepreneurs are powerful storytellers. This interactive bootcamp will show you how to shape and share your startup’s story for maximum investor impact. Learn how to sharpen your elevator pitch, refine your 12-slide deck, and make your messaging resonate with different stakeholders in the deal chain. Participants will leave with actionable language tools and techniques to boost their confidence and communication skills.


July 22, 2025 at 12:00 PM
Tips on Pitching: From the Application to the Q and A – Sign Up
Get a firsthand look at what makes a pitch resonate with investors. Join RESI judge, Bruce Cohen, who has sat on both sides of the table as an investor and an Innovator’s Pitch Challenge participant, for an inside perspective on how to stand out. This session covers best practices for your application, how to deliver a clear and convincing pitch, and how to prepare for and respond to investor Q and A.


August 7, 2025 at 12:00 PM
Biotech Exec Webinar – Who should be on your executive team? Structuring for success and fractional execs. – Sign Up
Join Life Science Nation (LSN) and Biotech Exec in early August for a free webinar on how to structure your life science startup executive team for success. Startups can fall victim to many strategic mistakes even when the science holds up. Choosing the right indication. Performing the right assay. Designing the right trial. Structuring a fund raise optimally. But one of the least talked about mistakes is putting the wrong people on the executive team or simply not brining on the right talent. We will have an engaging discussion that will include case studies of how things went wrong and testimonials from experienced CEOs and investors regarding what went right and what went wrong in their previous experience. Investors have a knack for knowing immediately if the executive team is poised to go the distance. Learn how to avoid the pitfalls most investors look for to ensure your barrier to fundraising is at a minimal. Learn if a fractional exec is right for you or if you should be looking for full-time right away.


August 18, 2025 at 12:00 PM
Partnering Tutorial: Making the Most of the RESI System – Sign Up
RESI’s partnering system is a powerful tool—but only if you know how to use it. Join the LSN team as we walk through how to navigate the platform, target the right investor fit, manage your outreach, and make the most of every meeting. We will also share our recommended strategy for follow-ups and how to leverage RESI content to support your fundraising journey.


September 4, 2025 at 12:00 PM
Investor Fireside Chat: Fundraising in Today’s Biotech Climate – Sign Up
Hear directly from investors about what is driving deal flow in the life science ecosystem. This fireside chat will cover current investment trends, what investors are looking for in early-stage biotech companies, and how startups can better position themselves to raise capital. Bring your questions and gain insight from experts who know what makes a company fundable.

Registration is open for all webinars. These sessions are free to attend and are designed to help you prepare for meaningful investor interactions and set yourself up for success at RESI Boston this September.